Health ยท South Africa

Aspen Pharmacare Wins Approval for Generic Semaglutide in Brazil and South Africa

South African drugmaker Aspen Pharmacare has won approval for a generic version of semaglutide in Brazil and South Africa. The available information does not name the regulators, give launch dates, pricing or product formulations, so this account is limited to the approvals themselves.

South African drugmaker Aspen Pharmacare has secured approval to market a generic version of semaglutide in two countries, Brazil and South Africa.

The approvals cover one of the company's home markets and one of the largest economies in Latin America. The information available gives no further detail on the decisions.

It does not name the regulatory bodies that granted the approvals, and it does not say when the approvals were issued. It does not describe the product or formulations that were cleared, or say which medical uses are covered. There is also no information on when the generic version might reach pharmacies or hospitals, how it will be priced, or what volumes Aspen expects to supply.

The company has not been quoted in the material provided, and there is no comment from regulators or health authorities in either country. Any commercial or public health implications of the approvals therefore cannot be established from the information supplied.

The announcement follows other recent corporate news involving Aspen Pharmacare, which is to sell a women's health product in Europe to Ennogen. That is a separate transaction and is not linked in the available information to the semaglutide approvals.

Further details are expected to emerge from the company or from the regulators concerned, and this account will need to be updated if they are published.

More reporting from Voice of Africans